Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sucralfate + oxetacaine + simethicone is a fixed-dose combination oral suspension used for the management of gastrointestinal disorders including peptic ulcers, gastritis, and gastroesophageal reflux disease (GERD) associated with flatulence. **Sucralfate** acts as a cytoprotective agent by adhering to ulcer sites and forming a protective proteinaceous barrier against acid, pepsin, and bile salts. **Oxetacaine** (also known as oxethazaine) is a potent local anesthetic that provides rapid symptomatic relief from pain by numbing the esophageal and gastric mucosa; it is unique for maintaining its anesthetic activity even in highly acidic environments. **Simethicone** serves as an anti-foaming agent that reduces the surface tension of gas bubbles in the digestive tract, facilitating their coalescence and expulsion to relieve bloating and gas-related discomfort. This combination is primarily marketed in India by companies such as Laksun Lifesciences.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sucralfate + oxetacaine + simethicone.